

Express Mail No. EV405281365US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	TECH-004
	First Named Inventor	TAKAHATA, KYOYA
	Application Number	10/634,641
	Confirmation No.	7194
	Filing Date	August 4, 2003
	Group Art Unit	1614
	Examiner Name	N/A
	Title:	"ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING N-VANILLYL FATTY ACID AMIDE"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. TECH-004 may be charged thereon.


Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: April 22, 2004

By:


Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/634,641	
			Filing Date	August 4, 2003	
			First Named Inventor	TAKAHATA, KYOYA	
			Art Unit	1614	
			Examiner Name	N/A	
Sheet	1	of	1	Attorney Docket Number	TECH-004

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code² (if known)				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁶
		Country Code³-Number⁴-Kind Code⁵ (if known)					

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		MORRE et al. "Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture" <i>Proc. Natl. Acad. Sci. USA</i> Vol. 92, pp. 1831-1835, March 1995	
		TAKAHATA et al. "Growth Inhibition of capsaicin on hela cells is not mediated by intracellular calcium mobilization" <i>Life Sciences</i>, Vol. 64, No. 13, pp. PL 165-171 (1999)	
		SZALLASI et al. "Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor" <i>Life Sciences</i> Vol. 47, pp. 1399-1408 (1990)	
		MORRE et al. "Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines" <i>European Journal of Cancer</i>, Vol. 32A, No. 11, pp. 1995-2003, (1996)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.